|  | Number | % |
---|---|---|---|
Sex | Male | 16 | 26.7 |
Female | 44 | 73.3 | |
Age (years) | < 40 | 3 | 5.0 |
40–49 | 15 | 25.0 | |
50–59 | 21 | 35.0 | |
60–69 | 13 | 21.7 | |
70–79 | 8 | 13.3 | |
≥ 80 | 0 | 0.0 | |
History | Allergy | 9 | 15.0 |
Experience of feeling unwell after receiving some vaccine | 5 | 8.3 | |
Vaccination status | Never | 2 | 3.3 |
1st dose | 58 | 96.7 | |
2nd dose | 58 | 96.7 | |
3rd dose | 47 | 78.3 | |
4th dose | 21 | 35.0 | |
Cancer stage | Stage 0 | 0 | 0.0 |
Stage I | 9 | 15.0 | |
Stage II | 13 | 21.7 | |
Stage III | 13 | 21.7 | |
Stage IV | 13 | 21.7 | |
Unknown | 12 | 20.0 | |
Duration of cancer treatment | < 1 years | 44 | 73.3 |
1–5 years | 9 | 15.0 | |
6–10 years | 5 | 8.3 | |
≥ 11 years | 2 | 3.3 | |
History of COVID-19 | Have a history of COVID-19 without the vaccination | 0 | 0.0 |
Have a history of COVID-19 before vaccination | 2 | 3.3 | |
Have a history of COVID-19 after vaccination | 12 | 20.0 | |
Have a history of COVID-19 both before and after vaccination | 1 | 1.7 | |
No history of COVID-19 | 45 | 75.0 |